Cargando…
Crystal Modifications of a Cyclic Guanosine Phosphorothioate Analogue, a Drug Candidate for Retinal Neurodegenerations
In contribution to the pharmaceutical development of cyclic guanosine monophosphorothioate analogue cGMPSA as a potential active pharmaceutical ingredient (API) for the treatment of inherited retinal degenerations (IRDs), its neutral form (cGMPSA‐H) and salts of sodium (‐Na), calcium (‐Ca), ammonium...
Autores principales: | Pérez, Oswaldo, Schipper, Nicolaas, Leandri, Valentina, Svensson, Per H., Bohlin, Martin, Loftsson, Thorsteinn, Bollmark, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695737/ https://www.ncbi.nlm.nih.gov/pubmed/37877436 http://dx.doi.org/10.1002/open.202300141 |
Ejemplares similares
-
Preparative Synthesis of an R(P)-Guanosine-3′,5′-Cyclic
Phosphorothioate
Analogue, a Drug Candidate for the Treatment of Retinal Degenerations
por: Pérez, Oswaldo, et al.
Publicado: (2021) -
Structural Characterization Study of a Lipid Nanocapsule
Formulation Intended for Drug Delivery Applications Using Small-Angle
Scattering Techniques
por: Urimi, Dileep, et al.
Publicado: (2022) -
Structural investigation into physiological DNA phosphorothioate modification
por: Lan, Wenxian, et al.
Publicado: (2016) -
DNA Phosphorothioate Modifications Are Widely Distributed in the Human Microbiome
por: Sun, Yihua, et al.
Publicado: (2020) -
Aqueous Prostaglandin Eye Drop Formulations
por: Jansook, Phatsawee, et al.
Publicado: (2022)